Learning objectives
- Diagnose perimenopause and menopause clinically, and know when testing helps.
- Select candidates for hormone therapy using age, timing and contraindications.
- Prescribe and monitor estrogen and progestogen, and offer non-hormonal options.
Perimenopause and diagnosis
Menopause is 12 months without a period. Perimenopause, the years before it, brings irregular cycles, hot flashes and night sweats, poor sleep, mood changes, brain fog, joint aches, and vaginal dryness.
- In women 45 and older with typical symptoms, diagnosis is clinical. FSH swings widely in perimenopause, so a single value is unreliable.
- Under 40: evaluate for primary ovarian insufficiency (FSH on two occasions, plus TSH, prolactin and hCG). These patients generally need hormone therapy until the average age of menopause.
- Contraception is still needed in perimenopause, until 12 months without a period for women over 50, or 24 months for women under 50.
- Bleeding after menopause always needs evaluation of the endometrium.
Candidacy and risks
The Menopause Society's 2022 position: for people under 60 or within 10 years of menopause, without contraindications, the benefits of hormone therapy generally outweigh the risks for bothersome vasomotor symptoms and for preventing bone loss.
| Risk | What we know |
|---|---|
| Breast cancer | Estrogen plus progestin: small increase with longer use (WHI: under 1 extra case per 1,000 women per year). Estrogen alone after hysterectomy did not increase risk in WHI. |
| Blood clots and stroke | Higher with oral estrogen. Transdermal estradiol appears to carry lower risk in observational data. |
| Heart disease | Starting near menopause appears neutral or favorable; starting 10+ years later or after 60 carries more risk. |
| Endometrial cancer | Unopposed estrogen raises risk. Anyone with a uterus needs a progestogen. |
Contraindications: unexplained vaginal bleeding, breast cancer or another estrogen-sensitive cancer, prior blood clot or stroke, coronary disease, active liver disease, and known high-risk thrombophilia.
Prescribing and monitoring
| Option | Typical start | Notes |
|---|---|---|
| Transdermal estradiol patch | 0.025 to 0.05 mg/day | Preferred with clot risk, migraine, or high triglycerides |
| Oral estradiol | 0.5 to 1 mg/day | Simple and inexpensive |
| Micronized progesterone | 100 mg nightly (continuous) or 200 mg for 12 days a month | For endometrial protection; may help sleep |
| Low-dose vaginal estrogen | Cream, tablet or ring | For genitourinary symptoms; minimal absorption; no progestogen needed; can continue long term |
- Dose by symptoms, not blood levels. Routine estradiol levels aren't needed.
- Use FDA-approved products. FDA-approved estradiol and progesterone are bioidentical. Compounded hormones and pellets are not FDA-approved, vary in dose, and pellets can produce very high levels.
- Testosterone for women has one evidence-based use: hypoactive sexual desire disorder after menopause, at doses appropriate for women, with monitoring.
- Duration is individualized. There's no automatic stop at 65; reassess yearly with mammography and a risk review.
- Non-hormonal options: fezolinetant (needs liver tests before and during treatment), low-dose paroxetine and other SSRIs or SNRIs, gabapentin, and CBT for hot flashes and sleep.
Clinical pearls
- Don't order FSH to diagnose perimenopause in a woman over 45 with typical symptoms.
- Every patient with a uterus who takes systemic estrogen needs a progestogen.
- Vaginal estrogen is low-risk and underused for urinary and vaginal symptoms.
Red flags: refer or work up first
- Any postmenopausal bleeding, or heavy or prolonged bleeding on hormone therapy.
- A new breast lump, or calf pain, chest pain, or shortness of breath on therapy.
- Menopause symptoms before 40: evaluate for primary ovarian insufficiency.
Case
A 51-year-old with 10 hot flashes a day, poor sleep and a last period 8 months ago has migraine without aura and a BMI of 33. She has her uterus. She asks about hormone therapy.
Show discussion
She is within 10 years of menopause and under 60, so hormone therapy is reasonable. Transdermal estradiol is preferred given migraine and higher BMI. Add micronized progesterone for endometrial protection. Confirm mammography is current, discuss that she still needs contraception for now, and follow up in about 3 months to adjust the dose.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.
- Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013.
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023.
- Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019.
- ACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy. 2023.
- U.S. FDA. Safety communication on fezolinetant (Veozah) and liver injury, boxed warning. 2024.
- Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. Menopause. 2012.
Perimenopause and menopause
Perimenopause can start in your 40s. Periods change, and hot flashes, night sweats, poor sleep, mood swings and vaginal dryness are common. You don't have to just put up with it.
- Hormone therapy is safe and effective for many women under 60 or within 10 years of menopause. We'll go over your own risks.
- Other options include non-hormone medicines and therapy for sleep and hot flashes.
- Vaginal estrogen is low-dose and helps dryness and urinary symptoms.
- You can still get pregnant in perimenopause. Keep using birth control until we tell you it's safe to stop.
Call us about any bleeding after your periods have stopped for a year, a new breast lump, or leg swelling or chest pain.
General education for licensed clinicians and the public. Not medical advice, and not a substitute for clinical judgment, current guidelines, or a visit with a licensed provider. Product names are examples, not endorsements. Drug doses, coding rules and guidance change; check current labeling, payer rules and guidelines before acting. Book a visit with Empowered Health.
